BMRN Latest Headlines

BioMarin Pharmaceutical Non-GAAP EPS of $0.23 beats by $0.34, revenue of $1.03B beats by $10M

at seekingalpha.com (Mon, 2-Nov 4:06 PM)

BioMarin Pharmaceutical Q3 2026 Earnings Preview

at seekingalpha.com (Sun, 1-Nov 5:35 PM)

BioMarin: Buy Rating Reiterated as Rare-Disease Portfolio, LA-GLA Deal & FOLD Acquisition Underscore Upside with Unchanged $114 Price Target

at www.tipranks.com (Fri, 30-Oct 12:55 PM)

Robert W. Baird Reaffirms Their Hold Rating on BioMarin Pharmaceutical (BMRN)

at www.tipranks.com (Wed, 28-Oct 2:45 AM)

BioMarin Sets Nov. 2 Q3 2026 Results Call as It Highlights a Rare-Disease Franchise with Nine Commercial Therapies

Market Chameleon (Mon, 26-Oct 9:18 AM)

BioMarin Highlights Growth Strategy Ahead of 2026 Canaccord Conference Presentation

Market Chameleon (Mon, 10-Aug 9:20 AM)